Dolby Laboratories Inc
For the period ended Jun 28, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 28, 2024 · Filed Aug 7, 2024
DLB$64.67-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance at March 29, 2024 | $94 | $— | $2,449,876 | $(29,068) | $2,420,902 | $16,785 | $2,437,687 |
| Net income | — | — | 38,444 | — | 38,444 | 1,211 | 39,655 |
| Other comprehensive loss, net of tax | — | — | — | (1,104) | (1,104) | 46 | (1,058) |
| Distributions to noncontrolling interest | — | — | — | — | — | (3,448) | (3,448) |
| Stock-based compensation expense | — | 29,337 | — | — | 29,337 | — | 29,337 |
| Capitalized stock-based compensation expense | — | 206 | — | — | 206 | — | 206 |
| Repurchase of common stock | (1) | (38,310) | 3,311 | — | (35,000) | — | (35,000) |
| Cash dividends declared and paid on common stock | — | — | (28,703) | — | (28,703) | — | (28,703) |
| Common stock issued under employee stock plans | 1 | 10,141 | — | — | 10,142 | — | 10,142 |
| Tax withholdings on vesting of restricted stock | — | (1,374) | — | — | (1,374) | — | (1,374) |
| Equity issued in connection with business combination | — | — | — | — | — | (12) | (12) |
| Balance at June 28, 2024 | $94 | $— | $2,462,928 | $(30,172) | $2,432,850 | $14,582 | $2,447,432 |
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveIncome/(Loss) | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance at September 29, 2023 | $94 | $— | $2,391,990 | $(36,984) | $2,355,100 | $17,084 | $2,372,184 |
| Net income | — | — | 203,255 | — | 203,255 | 2,195 | 205,450 |
| Other comprehensive income, net of tax | — | — | — | 6,812 | 6,812 | 125 | 6,937 |
| Distributions to noncontrolling interest | — | — | — | — | — | (4,495) | (4,495) |
| Stock-based compensation expense | — | 90,146 | — | — | 90,146 | — | 90,146 |
| Capitalized stock-based compensation expense | — | 411 | — | — | 411 | — | 411 |
| Repurchase of common stock | (2) | (92,974) | (47,023) | — | (139,999) | — | (139,999) |
| Cash dividends declared and paid on common stock | — | — | (85,971) | — | (85,971) | — | (85,971) |
| Common stock issued under employee stock plans | 2 | 39,485 | — | — | 39,487 | — | 39,487 |
| Tax withholdings on vesting of restricted stock | — | (37,428) | — | — | (37,428) | — | (37,428) |
| Deconsolidation of subsidiary | — | — | 677 | — | 677 | (677) | — |
| Equity issued in connection with business combination | — | 360 | — | — | 360 | 350 | 710 |
| Balance at June 28, 2024 | $94 | $— | $2,462,928 | $(30,172) | $2,432,850 | $14,582 | $2,447,432 |
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | Accumulated Other Comprehensive Loss | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance at March 31, 2023 | $95 | $— | $2,378,115 | $(27,426) | $2,350,784 | $5,208 | $2,355,992 |
| Net income | — | — | 16,399 | — | 16,399 | 6 | 16,405 |
| Other comprehensive income, net of tax | — | — | — | (3,737) | (3,737) | 77 | (3,660) |
| Stock-based compensation expense | — | 29,224 | — | — | 29,224 | — | 29,224 |
| Capitalized stock-based compensation expense | — | 389 | — | — | 389 | — | 389 |
| Repurchase of common stock | (1) | (53,635) | 28,636 | — | (25,000) | — | (25,000) |
| Cash dividends declared and paid on common stock | — | — | (25,843) | — | (25,843) | — | (25,843) |
| Common stock issued under employee stock plans | — | 15,837 | — | — | 15,837 | — | 15,837 |
| Tax withholdings on vesting of restricted stock | — | (1,819) | — | — | (1,819) | — | (1,819) |
| Equity issued in connection with business combination | — | 10,004 | — | — | 10,004 | 11,194 | 21,198 |
| Balance at June 30, 2023 | $94 | $— | $2,397,307 | $(31,163) | $2,366,238 | $16,485 | $2,382,723 |
| Dolby Laboratories, Inc. | |||||||
|---|---|---|---|---|---|---|---|
| CommonStock | AdditionalPaid-InCapital | RetainedEarnings | Accumulated Other Comprehensive Loss | Total Stockholders' Equity - DolbyLaboratories,Inc. | NoncontrollingInterest | Total Stockholders' Equity | |
| Balance at September 30, 2022 | $94 | $— | $2,297,730 | $(51,641) | $2,246,183 | $4,837 | $2,251,020 |
| Net income | — | — | 191,470 | — | 191,470 | 266 | 191,736 |
| Other comprehensive income, net of tax | — | — | — | 20,478 | 20,478 | 454 | 20,932 |
| Distributions to noncontrolling interest | — | — | — | — | — | (266) | (266) |
| Stock-based compensation expense | — | 90,291 | — | — | 90,291 | — | 90,291 |
| Capitalized stock-based compensation expense | — | 1,060 | — | — | 1,060 | — | 1,060 |
| Repurchase of common stock | (2) | (109,965) | (14,309) | — | (124,276) | — | (124,276) |
| Cash dividends declared and paid on common stock | — | — | (77,584) | — | (77,584) | — | (77,584) |
| Common stock issued under employee stock plans | 2 | 37,229 | — | — | 37,231 | — | 37,231 |
| Tax withholdings on vesting of restricted stock | — | (28,619) | — | — | (28,619) | — | (28,619) |
| Equity issued in connection with business combination | — | 10,004 | — | — | 10,004 | 11,194 | 21,198 |
| Balance at June 30, 2023 | $94 | $— | $2,397,307 | $(31,163) | $2,366,238 | $16,485 | $2,382,723 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.